The representative immunotherapy regiment PD-L1 inhibitor atezolizumab, combined with the anti-angiogenic drug bevacizumab, has achieved success in the first-line treatment of advanced HCC [37]. The gene discussed is CD274; the disease is hepatocellular carcinoma.